STAT+: Pharmalittle: Pfizer makes a major push into mRNA technology; Medicare decision on Alzheimer’s drug may hurt state budgets
A preliminary decision on Medicare coverage for the Biogen Alzheimer's drug is due this week, and it has major implications for state Medicaid programs.
by Ed Silverman
Jan 10, 2022
1 minute
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so familiar routine of
You’re reading a preview, subscribe to read more.
Start your free 30 days